Terug
49
Dagbereik
€ 5,94
€ 6,23
52-Weeksbereik
€ 5,94
€ 15,85
Volume
3.942.656
50D / 200D Gem.
€ 7,72
/
€ 8,64
Vorige Slotkoers
€ 6,09
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (627 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 8,5 | 0,3 |
| P/B | 2,1 | 2,9 |
| ROE % | 30,6 | 3,7 |
| Net Margin % | 3,0 | 3,8 |
| Rev Growth 5Y % | -0,4 | 10,0 |
| D/E | 11,7 | 0,2 |
Koersdoel Analisten
Hold
€ 6,50
+6.4%
Low: € 5,00
High: € 8,00
Forward K/W
1,8
Forward WPA
€ 3,47
WPA Groei (sch.)
+0,0%
Omzet Sch.
6,2 B
Winstschattingen
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| FY2030 |
€ 3,90
€ 3,79 – € 3,98
|
6,5 B | 1 |
| FY2029 |
€ 3,80
€ 3,70 – € 3,87
|
6,5 B | 1 |
| FY2028 |
€ 3,96
€ 3,85 – € 4,03
|
6,3 B | 1 |
Belangrijkste Punten
Revenue declined -0,35% annually over 5 years
Earnings declined -78,36% over the past year
ROE of 30,56% indicates high profitability
Debt/Equity of 11,70 — high leverage
Generating 538,00M in free cash flow
P/E of 8,51 — trading at a low valuation
Groei
Revenue Growth (5Y)
-0,35%
Revenue (1Y)-2,92%
Earnings (1Y)-78,36%
FCF Growth (3Y)0,00%
Kwaliteit
Return on Equity
30,56%
ROIC10,09%
Net Margin3,01%
Op. Margin20,67%
Veiligheid
Debt / Equity
11,70
Current Ratio1,82
Interest Coverage2,55
Waardering
P/E Ratio
8,51
P/B Ratio2,12
EV/EBITDA7,64
Dividend Yield0,05%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | -2,92% | Revenue Growth (3Y) | -0,38% |
| Earnings Growth (1Y) | -78,36% | Earnings Growth (3Y) | -57,25% |
| Revenue Growth (5Y) | -0,35% | Earnings Growth (5Y) | -39,00% |
| Profitability | |||
| Revenue (TTM) | 6,22B | Net Income (TTM) | 187,00M |
| ROE | 30,56% | ROA | 1,45% |
| Gross Margin | 54,09% | Operating Margin | 20,67% |
| Net Margin | 3,01% | Free Cash Flow (TTM) | 538,00M |
| ROIC | 10,09% | FCF Growth (3Y) | 0,00% |
| Safety | |||
| Debt / Equity | 11,70 | Current Ratio | 1,82 |
| Interest Coverage | 2,55 | Dividend Yield | 0,05% |
| Valuation | |||
| P/E Ratio | 8,51 | P/B Ratio | 2,12 |
| P/S Ratio | 0,26 | PEG Ratio | -0,13 |
| EV/EBITDA | 7,64 | Dividend Yield | 0,05% |
| Market Cap | 1,59B | Enterprise Value | 9,82B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 6,22B | 6,40B | 6,26B | 6,17B | 6,30B |
| Net Income | 187,00M | 864,00M | 1,02B | 917,00M | 1,35B |
| EPS (Diluted) | 0,72 | 3,33 | 3,99 | 3,59 | 5,33 |
| Gross Profit | 3,36B | 3,72B | 3,75B | 3,88B | 3,92B |
| Operating Income | 1,29B | 1,49B | 1,33B | 1,71B | 1,92B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 12,87B | 13,10B | 12,06B | 10,96B | 10,68B |
| Total Liabilities | 12,12B | 12,63B | 12,13B | 11,85B | 12,19B |
| Shareholders' Equity | 752,00M | 472,00M | -70,00M | -892,00M | -1,51B |
| Total Debt | 8,80B | 9,04B | 8,93B | 9,11B | 9,36B |
| Cash & Equivalents | 574,00M | 675,00M | 693,00M | 706,00M | 737,00M |
| Current Assets | 4,35B | 4,35B | 4,51B | 3,93B | 3,76B |
| Current Liabilities | 2,39B | 2,72B | 2,92B | 2,51B | 2,60B |
Strategiescores
This stock passed the criteria for 1 strategy
Score = fit strength (0–100)
Rank = position among all matches
#165 of 670
Recente Activiteit
Ingestapt
Contrarian Investing (David Dreman)
Mar 24, 2026